Experts from three American universities have assessed the benefits of the Russian Sputnik V vaccine. As the scientists noted, with the high demonstrated effectiveness of the drug against coronavirus infection, it does not require maintaining an ultra-low temperature for its storage and transportation. This is a significant difference between Sputnik V and a number of other COVID-19 vaccines.
In particular, Dean Winslow, an infectious disease specialist at the Stanford University Medical Center (California), said in a comment to TASS that the Russian drug, with its high efficiency, is a DNA vaccine, which does not require special conditions, unlike RNA vaccines.
Daniel Kuritskis, head of infectious diseases at Harvard University School of Medicine, Massachusetts, says the ability to store the vaccine “at the temperature that a normal refrigerator maintains” makes the drug much easier to use, including in countries with fewer storage options. at ultra-low temperature. At the same time, according to Kuritskis, "Sputnik V" is one of the drugs that in the future will help "put an end to the coronavirus pandemic."
After the publication of data from the third phase of trials in The Lancet, an infectious disease specialist from the University of Georgia at Augusta Roger MacArthur called Sputnik V a very promising vaccine, drawing attention to a fundamentally different technology used in the development of a Russian drug. MacArthur also pointed to the advantage in the absence of special storage and transportation conditions.